George Lemaitre Sells 27,881 Shares of LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George Lemaitre sold 27,881 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the completion of the sale, the chief executive officer owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

LeMaitre Vascular Trading Down 4.3%

NASDAQ LMAT opened at $97.22 on Wednesday. LeMaitre Vascular, Inc. has a one year low of $78.35 and a one year high of $118.01. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. The stock’s 50-day moving average is $109.87 and its 200-day moving average is $94.76. The firm has a market cap of $2.22 billion, a P/E ratio of 35.87, a P/E/G ratio of 2.82 and a beta of 0.60.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. During the same period last year, the business posted $0.48 earnings per share. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be paid a dividend of $0.25 per share. The ex-dividend date is Thursday, May 21st. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s payout ratio is currently 36.90%.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Negative Sentiment: CEO George W. Lemaitre sold two blocks of stock last week, including 27,881 shares and 18,600 shares, which can weigh on investor sentiment because executives selling shares often raises concerns about near-term upside. Article: LeMaitre Vascular CEO George Lemaitre Sells 27,881 Shares Article: LeMaitre Vascular CEO George Lemaitre Sells 18,600 Shares of Stock
• Negative Sentiment: Director Bridget A. Ross and insider Trent G. Kamke also sold shares, adding to the impression that management is trimming exposure across multiple levels of the company. Article: LeMaitre Vascular Director Bridget Ross Sells 5,044 Shares of Stock Article: LeMaitre Vascular Insider Trent Kamke Sells 2,928 Shares
• Neutral Sentiment: Short interest data showed essentially no short positions, so short-selling does not appear to be a meaningful driver of the stock move. Article: LeMaitre Vascular Insider Trent Kamke Sells 2,928 Shares
• Positive Sentiment: Recent earnings were stronger than expected, with Q1 EPS of $0.68 beating estimates and revenue rising 11.1% year over year, and management also raised FY2026 guidance; these fundamentals help support the longer-term outlook. LeMaitre Vascular stock report

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in LeMaitre Vascular by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after buying an additional 21,946 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in LeMaitre Vascular by 3.6% in the 1st quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock valued at $161,224,000 after buying an additional 51,825 shares in the last quarter. First Trust Advisors LP grew its holdings in LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after buying an additional 111,193 shares in the last quarter. State Street Corp grew its holdings in LeMaitre Vascular by 0.8% in the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock valued at $65,447,000 after buying an additional 6,130 shares in the last quarter. Finally, Congress Asset Management Co. grew its holdings in LeMaitre Vascular by 5.8% in the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analyst Ratings Changes

LMAT has been the topic of several recent analyst reports. Citizens Jmp boosted their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Barrington Research boosted their target price on LeMaitre Vascular from $105.00 to $120.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Finally, Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.